Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02477670 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
- 17
- Study locations
NCT02477670: Completed Phase 2 study of Schizophrenia, sponsored by Avanir Pharmaceuticals.
NCT02477670 is a Phase 2 study of Schizophrenia that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 145 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (34% lower). The trial reports 17 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02477670, a Phase 2 study of Schizophrenia, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
- 17
- Study locations
Study Summary
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Primary Outcome
The NSA-16 is a measure of the presence, severity, and range of negative symptoms associated with schizophrenia. It has a high interrater and test-retest reliability across languages and cultures. The NSA-16 uses a 5-factor model to describe negative symptoms: (1) communication, (2) emotion/affect, (3) social involvement, (4) motivation, and (5) retardation. The possible NSA-16 total score ranges from 16 to 96, with a higher score indicating a worse condition. Change was Baseline was calculated
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AVP-786
Study Locations (17)
California
- - Cerritos
- - Garden Grove
- - National City
- - Oakland
- - San Diego
New York
- - Jamaica
- - New York
- - Rochester
Georgia
- - Atlanta
- - Augusta
Massachusetts
- - Boston
- - Worcester
District of Columbia
- - Washington D.C.
Florida
- - Orlando
Illinois
- - Chicago
Michigan
- - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-07-21 |
| Phase | Phase 2 |
What the finished NCT02477670 record still lists
NCT02477670 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02477670 lists 17 locations in 9 states (California, New York, Georgia).
Frequently Asked Questions
What is clinical trial NCT02477670 about?
NCT02477670 is a clinical study titled "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia". The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
What is the current status of trial NCT02477670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2015-09. Estimated completion is 2017-07-21.
What conditions does trial NCT02477670 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02477670?
The interventions under investigation include: Placebo (DRUG), AVP-786 (DRUG).
Who is sponsoring clinical trial NCT02477670?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02477670 being conducted?
This trial has 17 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02477670's enrollment target sits among peer trials
145 109th of 315 higher than 207 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia